Additional Clinical Considerations With CDK4/6 Inhibitors

Panelists explore how prolonged exposure to CDK4/6 inhibitors raises important questions about optimal therapy duration and resistance patterns. As survival improves, clinicians must determine when to continue, switch, or discontinue treatment. Emerging data suggest that careful monitoring of clinical and molecular markers may guide these complex decisions.

The discussion also focuses on quality-of-life considerations, with panelists emphasizing that maintaining daily function and emotional well-being are as vital as extending survival. Fatigue and psychological burden are addressed through holistic care models that include psychosocial support and patient education.

In conclusion, ongoing collaboration among providers helps balance disease control with patient-centered priorities, ensuring that therapy aligns with both medical and personal goals.